Meanwhile, for patients with EGFR-positive operable NSCLC, some studies of neoadjuvant targeted therapy with EGFR-TKI agents or combined with neoadjuvant chemotherapy are also underway. Here, EGFR is linked to non-small cell lung carcinoma.